OncoSec Medical Inc (ONCSQ)

[guti]

I see you saw my post, just wanted to add that in cancer care, durable response has to do with a long-lasting positive reaction to tumor therapy, usually lasting at least a year. On June 2,2017 Merck presented findings to a study for advanced melanoma showing durable responses with Keytruda after treatment follow up of nearly three years:

"In the longer-term findings to be presented, treatment with KEYTRUDA was associated with a 30 percent improvement in survival: 50 percent of patients in the KEYTRUDA group (based on a pooled analysis of the two doses studied: 10 mg/kg every two weeks or 10 mg/kg every three weeks; n=556) were alive nearly three years (33.9 months) after starting treatment with KEYTRUDA, compared to 39 percent of patients in the ipilimumab group (n=278) (HR: 0.70 [95% CI, 0.58-0.86]). In addition, KEYTRUDA nearly doubled the rate of progression-free survival (PFS) at 33.9 months: 31 percent of patients in the KEYTRUDA group were alive and their disease had not progressed, compared to 14 percent of patients in the ipilimumab group."